tradingkey.logo
tradingkey.logo

US FDA extends review of Lantheus' diagnostic imaging kit by three months

ReutersMar 17, 2026 8:16 PM

- Lantheus Holdings LNTH.O said on Tuesday that the U.S. Food and Drug Administration has extended its review of the company's diagnostic imaging kit by three months.

The agency will now give its decision on the imaging kit's approval by June 29.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI